Myricx Bio, a UK biotech company, has appointed Robert McLeod as vice president clinical development, effective 13 September. Dr McLeod will be responsible for developing clinical strategy and investigational new drug (IND) submissions for advancing the company’s antibody drug conjugates (ADC) pipeline towards clinical trials. Myricx Bio, the trading name of Myricx Pharma Ltd, is a spin out from Imperial College London, UK and the Francis Crick Institute.
With over 20 years’ experience in drug development and expertise in ADC clinical development, Dr. McLeod was previously a senior director and global clinical lead at Daiichi Sankyo Co Ltd where he worked on several ADCs across multiple solid tumour types. Prior to Daiichi Sankyo, Dr. McLeod was a research physician at Cancer Research UK's Centre for Drug Development. He received his medical degree from the University of Melbourne, Australia, holds an MBA from ESCP Business School in Paris, France, a diploma in pharmaceutical medicine and is a fellow of the UK Faculty of Pharmaceutical Medicine.
Copyright Evernow Publishing Ltd